Humanized EL4-hCD20-LZ reporter tumor cell line
![](https://cdn.prod.website-files.com/655b5a3d3d76e4eff6481da2/65b8bfab03e1c9348d5cf86f_cellule%201.png)
![](https://cdn.prod.website-files.com/655b5a3d3d76e4eff6481da2/65b8bfaacbee85e6e81e44c3_souris%201.png)
![](https://cdn.prod.website-files.com/655b5a3d3d76e4eff6481da2/65b8bfabf5f00b3aaec82ebf_rat%201.png)
Design of the EL4-hCD20-LZ cell line
The EL-4 cell line was established from a C57BL/6 murine lymphoma. These cells form tumors in syngeneic models, upon subcutaneous and systemic (i.v.) injection, in immunocompetent mice.
We generated an EL4-hCD20-LZ clonal cell line expressing high levels of human CD20 (MS4A1 NCBI GeneID: 931), and an optimized dual fusion reporter luciferase-ZsGreen (LZ). EL4-hCD20-LZ cells form tumors in vivo when injected systemically. Luciferase-ZsGreen (LZ) control cells are available.
EL4-hCD20-LZ features
- Express a fully human CD20
- Express a luciferase-ZsGreen (LZ) fusion reporter
- Form tumors and impact survival upon systemic injection in fully immunocompetent mice
- Luciferase from injected cells can be detected by in vivo imaging
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/65b1208112fc6da9dfeeea5e_img12.webp)
Validation
EL4-hCD20-LZ cells homogeneously express human CD20 in vitro
Expression analysis by flow cytometry. Human CD20 expression was assessed in EL4 parental cell line (left), human control cells – PBMC (center), and EL4-hCD20-LZ cell line (right).
EL4-hCD20-LZ cells impair survival in systemic syngeneic model
Wild-type C57/Bl6 mice were injected (i.v.) with 2x104 EL4-hCD20-LZ cells (red) or EL4 parental cells (blue), or with PBS (dotted black). Survival was followed over 37 days.
Discover related products to
EL4-hCD20-LZ
Humanized EL4-hCD20-LZ reporter tumor cell line
Get in touch about
Let us know how we can help
Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our modelsScientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in FranceCustomer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfactionCollaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate